Prothrombin time (PT): Research Studies

5 Related Result(s)

  1. Clinical Effectiveness of Standard Versus Mirasol-treated Apheresis Platelets in Patients with Hypoproliferative Thrombocytopenia

    To determine if the hemostatic efficacy of Mirasol-treated plasma stored Apheresis (Aph) PLTs are non-inferior to standard plasma stored Aph PLTs in patients...

  2. Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer

    To determine the efficacy, based on PFS, of mFOLFOX6/bevacizumab plus atezolizumab (combination) and atezolizumab (single agent) as compared to mFOLFOX6...

  3. Efficacy of Mirasol-treated Apheresis Platelets in Patients With Hypoproliferative Thrombocytopenia

    This is a prospective, multi-center, controlled, randomized, non-inferiority study to evaluate the clinical effectiveness of Conventional versus Mirasol...

  4. Phase 1a/1b Dose Escalation and Expansion Study of SBP-101 in Combination with Nab-Paclitaxel and Gemcitabine in Subjects with Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma

    The primary objective of the Phase 1a dose-escalation study is to determine the RD and DLTs of SBP-101 when administered in combination with standard dose...

  5. A Phase 1b Dose Escalation Study of OXi4503 as a Single Agent and in Combination with Cytarabine with Subsequent Combination Phase 2 Cohorts for Subjects with Relapsed/Refractory Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndromes (MDS)

    Phase 1: Determine the maximum tolerated dose (MTD) of OXi4503 as a single agent and in combination with intermediate-dose cytarabine in subjects with...